A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: next (883), subsequent (588)

Professor Graham Burdge

Description
Professor Graham Burdge Graham Burdge passed away at home on the 1st February 2024 as the result of a brain tumour. Graham lived with cancer for many years,
Url
/Media/Southampton-Clinical-Research/Downloads/Professor-Graham-Burdge.pdf

InP-Cisplatin-Doxorubicin-Methotrexate (1-4)

Description
Chemotherapy Protocol Sarcoma CISPLATIN-DOXORUBICIN-METHOTREXATE (cycles 1-4) Inpatient Regimen There are multiple versions of this
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-Cisplatin-Doxorubicin-Methotrexate-1-4.pdf

Endometrial Carboplatin-Cisplatin-PaclitaxelRT(21day)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-CISPLATIN-PACLITAXEL RT Regimen • Endometrial-Carbopla
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Endometrial-Carboplatin-Cisplatin-Paclitaxel-RT-21day.pdf

Bevacizumab (7.5mgkg), Carboplatin(AUC5) and Paclitaxel (21 day)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (7.5)-CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • Ovary-
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab7.5mgkgCarboplatinandPaclitaxel21day.pdf

Finance and Performance Reports 2021-22 month 4 July 2021

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Issue to be addressed: Finance Report
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2021-Trust-document/Finance-and-performance-reports/Finance-and-Performance-Reports-2021-22-Month-4-July-2021.pdf

Carboplatin(AUC6)-Gemcitabine

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC6)-GEMCITABINE Regimen  NSCLC – Carboplatin (AUC6)-Gemcit
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-AUC6-Gemcitabine.pdf

Carboplatin-Etoposide

Description
Regimen Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CARBOPLATIN (AUC6)-ETOPOSIDE (Intravenous / Oral) • SCLC – Carboplatin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Carboplatin-Etoposide-intravenous-and-oral.pdf

Carboplatin (AUC6) Retreat

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN Retreat Regimen (AUC6) • Ovary – Carboplatin (AUC6) Retreat Indication • Second line or subsequent tr
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC6Retreat.pdf

Carboplatin-Vinorelbine-IV-RT

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN-VINORELBINE-RADIOTHERAPY (Intravenous) Regimen • NSCLC – Carboplatin-Vinore
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Vinorelbine-IV-RT.pdf

Dacomitinib

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DACOMITINIB Regimen • NSCLC - Dacomitinib Indication Dacomitinib for untreated EGFR-positive non-small
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Dacomitinib.pdf
541 to 550 of 1000
Previous … 53 54 55 56 57 … Next